NTLA supply chain intelligence for Intellia Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| JEFFERIES | JEFFERIES | 92% | We will continue to pay Jefferies compensation for its services in cash up to 3.0% of the gross proceeds from the sale of shares of Common Stock pursuant to the terms of the amended Sales Agreement. |
| NOVARTIS-INSTITUTES-FOR-BIOMEDICAL-RESEARCH-INC | NOVARTIS-INSTITUTES-FOR-BIOMEDICAL-RESEARCH-INC | 90% | we have in-licensed by us for use with all genome editing technologies, including CRISPR/Cas9 products |
| RECODE | RECODE | 85% | ReCode and Intellia will focus initial research efforts on therapeutic approaches that address CF for patients who have limited or no treatment options available |
| CRBU | Caribou Biosciences, Inc. | 72% | Reciprocal relationship from CRBU graph: mulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is recorded in the statements of operations. Repairs a… |
| KYTX | Kyverna Therapeutics, Inc. | 72% | Reciprocal relationship from KYTX graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from KYTX graph: certain regulatory-and clinical-related benchmarks are due to the NIH, with … |
| MGX | Metagenomi Therapeutics, Inc. | 72% | Reciprocal relationship from MGX graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from MGX graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from MGX grap… |
| PRME | Prime Medicine, Inc. | 72% | Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable… |
| VRTX | Vertex Pharmaceuticals Incorporated | 72% | Reciprocal relationship from VRTX graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from VRTX graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from VRTX g… |
| ONK-THERAPEUTICS-LTD | ONK-THERAPEUTICS-LTD | 70% | The Company has existing license and collaboration agreements with AvenCell, Kyverna, and ONK Therapeutics, Ltd. ("ONK"). |
| AVENCELL | AVENCELL | 60% | The Company's other investments consist of investments in private companies including SparingVision and AvenCell, both of which are accounted for under ASC 321, Investments in Equity Securities. |
| KYVERNA | KYVERNA | 60% | The Company's other investments consist of investments in private companies including SparingVision and AvenCell, both of which are accounted for under ASC 321, Investments in Equity Securities. |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| REGENERON | REGENERON | 80% | The Company had no material revenue from these collaborations during the three months ended March 31, 2026 and 2025. |
| CRBU | Caribou Biosciences, Inc. | 72% | Reciprocal relationship from CRBU graph: cts from countries where our product candidates may be sold at lower prices than in the United States. 60 Table of Contents Third-party payors, whether domest… |
| KYTX | Kyverna Therapeutics, Inc. | 72% | . The Company had material revenue from Kyverna or ONK during the years ended December 31, 2025, 2024 or 2023. $ Other investments Restricted cash equivalents, long-term Prepaid expenses and other as… |
| KYTX | Kyverna Therapeutics, Inc. | 72% | Reciprocal relationship from KYTX graph: certain regulatory-and clinical-related benchmarks are due to the NIH, with the minimum cumulative royalty due for a product reaching FDA approval or foreign-… |
| MGX | Metagenomi Therapeutics, Inc. | 72% | Reciprocal relationship from MGX graph: amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, t… |
| PRME | Prime Medicine, Inc. | 72% | Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from NTLA graph: ize any potential product candidate. • Negative public opinion and increased regulatory scrutiny of CRISPR use, genom… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | ize any potential product candidate. • Negative public opinion and increased regulatory scrutiny of CRISPR use, genome editing or gene therapy may damage public perception of the safety of our produc… |
| AVENCELL-THERAPEUTICS-INC | AVENCELL-THERAPEUTICS-INC | 62% | 3 and 2022. As of December 31, 2024, the Company’s investment in Kyverna is valued at $ 4.4 million . The Company recognized an unrealized loss of $ 5.6 million , recorded within “change in fair valu… |
| RECODE-THERAPEUTICS-INC | RECODE-THERAPEUTICS-INC | 62% | basis, the financial condition and near-term prospects of the investee, and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recove… |
| REWRITE-THERAPEUTICS-INC | REWRITE-THERAPEUTICS-INC | 62% | itially recorded at fair value, determined according to Level 3 inputs in the fair value hierarchy described above. The SparingVision investment is included in “Investments and other assets” on the c… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| NTLA-DEBT | Debt stack $80.5M | 90% | Market cache reports total debt of $80.5M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| NTLA-OWNER-ARK-INVESTMENT-MANAGEMENT-LLC | ARK Investment Management LLC | 90% | 13F overlay lists ARK Investment Management LLC as top holder; 310 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 1 | ['receiving', 'spend'] |
| CRSP | CRISPR Therapeutics AG | 100.00 | 2 | |
| AUTL | Autolus Therapeutics plc | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| CRBU | Caribou Biosciences, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| DTIL | Precision BioSciences, Inc. | 100.00 | 1 | ['receiving'] |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| BCYC | Bicycle Therapeutics plc | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| LGND | Ligand Pharmaceuticals Incorporated | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 1 | ['customer'] |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 1 | ['receiving'] |
| NVO | Novo Nordisk A/S | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| ATRA | Atara Biotherapeutics, Inc. | 100.00 | 2 | |
| ACET | Adicet Bio, Inc. | 100.00 | 2 |